^
    5d
    STAR-121: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1069, Recruiting, Gilead Sciences | Trial completion date: Jun 2028 --> Jan 2029
    Trial completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF mutation • ALK mutation • RET mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154)
    6d
    Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) (clinicaltrials.gov)
    P2, N=122, Not yet recruiting, Hospices Civils de Lyon
    New P2 trial
    |
    5-fluorouracil • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)
    11d
    AB02: A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) (clinicaltrials.gov)
    P3, N=1100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • rilvegostomig (AZD2936)
    13d
    AB154 Combined With AB122 for Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Yale University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    Yutuo (zimberelimab) • domvanalimab (AB154)
    14d
    Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    nilvanstomig (ZG005)
    15d
    Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    nilvanstomig (ZG005)
    15d
    ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma (clinicaltrials.gov)
    P1/2, N=350, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    alveltamig (ZG006) • nilvanstomig (ZG005)
    15d
    Study of ZGGS15 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Completed, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Jun 2025 | Trial primary completion date: Aug 2026 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    ZGGS15
    15d
    Study of ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=100, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    nilvanstomig (ZG005)
    15d
    Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ZGGS18 • nilvanstomig (ZG005)
    15d
    Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • nilvanstomig (ZG005)
    25d
    Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Massachusetts General Hospital | Not yet recruiting --> Withdrawn
    Trial withdrawal
    |
    docetaxel • 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154)